These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15509168)

  • 1. Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
    Cogan PS; Koch TH
    J Med Chem; 2004 Nov; 47(23):5690-9. PubMed ID: 15509168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate.
    Cogan PS; Koch TH
    J Med Chem; 2003 Nov; 46(24):5258-70. PubMed ID: 14613328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
    Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
    J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility.
    Marcelli M; Stenoien DL; Szafran AT; Simeoni S; Agoulnik IU; Weigel NL; Moran T; Mikic I; Price JH; Mancini MA
    J Cell Biochem; 2006 Jul; 98(4):770-88. PubMed ID: 16440331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
    Burke PJ; Koch TH
    J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The androgen receptor and prostate cancer invasion.
    Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E
    Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
    Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
    Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
    Burke PJ; Kalet BT; Koch TH
    J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line.
    Paris F; Rabeolina F; Balaguer P; Bacquet A; Sultan C
    Gynecol Endocrinol; 2007 Apr; 23(4):193-7. PubMed ID: 17505938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
    Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
    Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.